Literature DB >> 12767667

Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure.

Anju Nohria1, Sui W Tsang, James C Fang, Eldrin F Lewis, John A Jarcho, Gilbert H Mudge, Lynne W Stevenson.   

Abstract

OBJECTIVES: This study was designed to determine the relevance of a proposed classification for advanced heart failure (HF). Profiles based on clinical assessment of congestion and perfusion at the time of hospitalization were compared with subsequent outcomes.
BACKGROUND: Optimal design of therapy and trials for advanced HF remains limited by the lack of simple clinical profiles to characterize patients.
METHODS: Prospective analysis was performed for 452 patients admitted to the cardiomyopathy service at the Brigham and Women's Hospital with a diagnosis of HF. Patients were classified by clinical assessment into four profiles: profile A, patients with no evidence of congestion or hypoperfusion (dry-warm, n = 123); profile B, congestion with adequate perfusion (wet-warm, n = 222); profile C, congestion and hypoperfusion (wet-cold, n = 91); and profile L, hypoperfusion without congestion (dry-cold, n = 16). Other standard predictors of outcome were included and patients were followed for the end points of death (n = 117) and death or urgent transplantation (n = 137) at one year.
RESULTS: Survival analysis showed that clinical profiles predict outcomes in HF. Profiles B and C increase the risk of death plus urgent transplantation by univariate (hazard ratio [HR] 1.83, p = 0.02) and multivariate analyses (HR 2.48, p = 0.003). Moreover, clinical profiles add prognostic information even when limited to patients with New York Heart Association (NYHA) class III/IV symptoms (profile B: HR 2.23, p = 0.026; profile C: HR 2.73, p = 0.009).
CONCLUSIONS: Simple clinical assessment can be used to define profiles in patients admitted with HF. These profiles predict outcomes and may be used to guide therapy and identify populations for future investigation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12767667     DOI: 10.1016/s0735-1097(03)00309-7

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  111 in total

Review 1.  Pathophysiology and clinical evaluation of acute heart failure.

Authors:  Robert J Mentz; Christopher M O'Connor
Journal:  Nat Rev Cardiol       Date:  2015-09-15       Impact factor: 32.419

Review 2.  Drugs' development in acute heart failure: what went wrong?

Authors:  Vincenzo Teneggi; Nithy Sivakumar; Deborah Chen; Alex Matter
Journal:  Heart Fail Rev       Date:  2018-09       Impact factor: 4.214

3.  Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction.

Authors:  Senthil Selvaraj; Brian Claggett; Sanjiv J Shah; Inder S Anand; Jean L Rouleau; Akshay S Desai; Eldrin F Lewis; Muthiah Vaduganathan; Stephen Y Wang; Bertram Pitt; Nancy K Sweitzer; Marc A Pfeffer; Scott D Solomon
Journal:  Circ Heart Fail       Date:  2019-06-21       Impact factor: 8.790

4.  Value of clinician assessment of hemodynamics in advanced heart failure: the ESCAPE trial.

Authors:  Mark H Drazner; Anne S Hellkamp; Carl V Leier; Monica R Shah; Leslie W Miller; Stuart D Russell; James B Young; Robert M Califf; Anju Nohria
Journal:  Circ Heart Fail       Date:  2008-09       Impact factor: 8.790

5.  Therapeutic options in advanced heart failure.

Authors:  Tarek Bekfani; Florian Westphal; P Christian Schulze
Journal:  Clin Res Cardiol       Date:  2018-07-09       Impact factor: 5.460

Review 6.  Systems of Care in Cardiogenic Shock.

Authors:  Maria M Patarroyo Aponte; Carlos Manrique; Biswajit Kar
Journal:  Methodist Debakey Cardiovasc J       Date:  2020 Jan-Mar

Review 7.  Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).

Authors:  Veli-Pekka Harjola; Wilfried Mullens; Marek Banaszewski; Johann Bauersachs; Hans-Peter Brunner-La Rocca; Ovidiu Chioncel; Sean P Collins; Wolfram Doehner; Gerasimos S Filippatos; Andreas J Flammer; Valentin Fuhrmann; Mitja Lainscak; Johan Lassus; Matthieu Legrand; Josep Masip; Christian Mueller; Zoltán Papp; John Parissis; Elke Platz; Alain Rudiger; Frank Ruschitzka; Andreas Schäfer; Petar M Seferovic; Hadi Skouri; Mehmet Birhan Yilmaz; Alexandre Mebazaa
Journal:  Eur J Heart Fail       Date:  2017-05-30       Impact factor: 15.534

Review 8.  A Standardized and Comprehensive Approach to the Management of Cardiogenic Shock.

Authors:  Behnam N Tehrani; Alexander G Truesdell; Mitchell A Psotka; Carolyn Rosner; Ramesh Singh; Shashank S Sinha; Abdulla A Damluji; Wayne B Batchelor
Journal:  JACC Heart Fail       Date:  2020-11       Impact factor: 12.035

Review 9.  Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond.

Authors:  John R Teerlink; Marco Metra; Valerio Zacà; Hani N Sabbah; Gadi Cotter; Mihai Gheorghiade; Livio Dei Cas
Journal:  Heart Fail Rev       Date:  2009-12       Impact factor: 4.214

10.  Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials.

Authors:  Marco Metra; Eric Eichhorn; William T Abraham; Jennifer Linseman; Michael Böhm; Ramon Corbalan; David DeMets; Teresa De Marco; Uri Elkayam; Michael Gerber; Michel Komajda; Peter Liu; Vyacheslev Mareev; Sergio V Perrone; Philip Poole-Wilson; Ellen Roecker; Jennifer Stewart; Karl Swedberg; Michal Tendera; Brian Wiens; Michael R Bristow
Journal:  Eur Heart J       Date:  2009-12       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.